Immix Biopharma, Inc. (ImmixBio TM) is a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx) TM in oncology and inflammation. Our lead asset, IMX-110, is currently in phase 1b/2a clinical trials for solid tumors in the United States and Australia. Our proprietary System Multi-Action RegulaTors SMAR xT Tissue-Specific TM Platform produces drugs that accumulate at intended therapeutic sites at 3-5 times that of conventional medicines. Our TME Normalization™ Technology allows our drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the tumor micro-environment, or TME. We have uncovered fundamental biological systems that link oncology and inflammation. Our pipeline includes pre-clinical tissue-specific therapeutics to treat inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. We use systems biology principles for rapid candidate selection and effective pre-clinical studies, leading to efficient manufacturing/scale up processes, toxicology and IP, followed by selection of appropriate contract research organizations and high-speed enrollment clinical trial sites.
ImmixBio was founded in 2012 by a visionary physician/entrepreneur, a world-renown pharmacology & drug delivery expert, a seasoned biotechnology patent attorney and an impact-driven founding family office.
Achieving impactful patient outcomes is what guides Immix. The team are not just experts in their fields – they have also been personally touched by cancer. With this deeply personal impetus, ImmixBio’s objective is a qualitative response in each patient – nothing short.
In memory of Donald E. Senn, Ph.D. who tragically lost his life to cancer at the height of a vibrant career as a biomedical scientist, and to all of the cancer patients and their families around the world who continue their brave fight.